Free Trial

argenex (ARGX) Stock Forecast & Price Target

argenex logo
$814.17 -20.58 (-2.47%)
Closing price 10/22/2025 04:00 PM Eastern
Extended Trading
$808.71 -5.46 (-0.67%)
As of 09:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

argenex - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
3
Buy
21

Based on 24 Wall Street analysts who have issued ratings for argenex in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 24 analysts, 3 have given a hold rating, 20 have given a buy rating, and 1 has given a strong buy rating for ARGX.

Consensus Price Target

$817.53
0.41% Upside
According to the 24 analysts' twelve-month price targets for argenex, the average price target is $817.53. The highest price target for ARGX is $1,070.00, while the lowest price target for ARGX is $680.00. The average price target represents a forecasted upside of 0.41% from the current price of $814.17.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for ARGX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for argenex and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ARGX Analyst Ratings Over Time

TypeCurrent Forecast
10/23/24 to 10/23/25
1 Month Ago
9/23/24 to 9/23/25
3 Months Ago
7/25/24 to 7/25/25
1 Year Ago
10/24/23 to 10/23/24
Strong Buy
1 Strong Buy rating(s)
3 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
20 Buy rating(s)
20 Buy rating(s)
19 Buy rating(s)
17 Buy rating(s)
Hold
3 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
4 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$817.53$789.20$728.06$550.44
Forecasted Upside0.41% Upside7.46% Upside22.99% Upside-1.34% Downside
Consensus RatingModerate BuyBuyBuyModerate Buy

ARGX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ARGX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

argenex Stock vs. The Competition

TypeargenexMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.33
2.52
Consensus RatingBuyHoldModerate Buy
Predicted Upside0.41% Upside1,456.32% Upside12.70% Upside
News Sentiment Rating
Positive News

See Recent ARGX News
Neutral News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/21/2025Zacks Research
0 of 5 stars
 DowngradeStrong-BuyHold
10/13/2025Wedbush
4 of 5 stars
Boost TargetOutperform$800.00 ➝ $880.00+10.43%
10/8/2025Weiss Ratings
0 of 5 stars
 Reiterated RatingHold (C)
10/1/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$766.00 ➝ $1,040.00+33.17%
9/18/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Target$882.00+20.53%
9/18/2025Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$1,070.00+45.62%
9/15/2025Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$700.00 ➝ $918.00+21.37%
9/11/2025Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeBuyHold
9/2/2025Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$880.00 ➝ $887.00+25.76%
8/26/2025Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Set TargetBuy$818.00+16.11%
8/26/2025Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$750.00 ➝ $820.00+17.27%
8/25/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$850.00+28.79%
8/4/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$775.00 ➝ $830.00+22.16%
8/1/2025HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$720.00 ➝ $774.00+15.47%
7/31/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$741.00 ➝ $756.00+12.78%
5/21/2025Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingBuy
5/14/2025JMP Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Target$699.00+30.93%
5/13/2025Baird R W
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldStrong-Buy
5/13/2025Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutralOutperform$680.00 ➝ $680.00+21.23%
5/9/2025Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$704.00 ➝ $708.00+27.59%
3/17/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeMarket PerformOutperform
2/28/2025William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
11/21/2024Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetOutperform$675.00 ➝ $706.00+19.29%
11/12/2024Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradePeer PerformOutperform$697.00+18.35%
11/5/2024Scotiabank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSector PerformSector Outperform$439.00 ➝ $715.00+21.46%
10/10/2024Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingStrong-Buy$605.00+16.23%
8/6/2024Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeEqual WeightOverweight
12/12/2023TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetOutperform$612.00 ➝ $641.00+41.35%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 09:05 AM ET.


Should I Buy argenex Stock? ARGX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, October 15, 2025. Please send any questions or comments about these argenex pros and cons to contact@marketbeat.com.

argenex
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in argenx SE:

  • The current stock price is around $720, which reflects strong market interest and potential for growth.
  • Recent earnings per share (EPS) of $3.74 exceeded analysts' expectations, indicating robust financial performance.
  • The company reported a significant revenue of $866.79 million, surpassing consensus estimates, showcasing strong sales growth.
  • With a market capitalization of approximately $48.77 billion, argenx SE is positioned as a major player in the biotechnology sector, attracting institutional investors.
  • Analysts have a positive outlook, with many rating the stock as "Buy" and setting target prices significantly above the current price, suggesting potential for appreciation.

argenex
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in argenx SE for these reasons:

  • The price-to-earnings ratio of 40.87 indicates that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • Despite strong performance, the stock has a beta of 0.46, suggesting lower volatility, which may not appeal to investors seeking high-risk, high-reward opportunities.
  • Institutional ownership is at 60.32%, which could lead to increased volatility if large investors decide to sell their positions.
  • While the company has a strong net margin of 40.98%, any downturn in revenue could significantly impact profitability and investor confidence.
  • Recent target price increases by analysts may create unrealistic expectations, leading to potential disappointment if future performance does not meet these projections.

ARGX Forecast - Frequently Asked Questions

According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for argenex is $817.53, with a high forecast of $1,070.00 and a low forecast of $680.00.

24 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for argenex in the last year. There are currently 3 hold ratings, 20 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ARGX shares.

According to analysts, argenex's stock has a predicted upside of 0.41% based on their 12-month stock forecasts.

Over the previous 90 days, argenex's stock had 2 downgrades and 1 upgrade by analysts.

Analysts like argenex more than other "medical" companies. The consensus rating for argenex is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how ARGX compares to other companies.


This page (NASDAQ:ARGX) was last updated on 10/23/2025 by MarketBeat.com Staff
From Our Partners